NOS2 and metabolic syndrome: Pioglitazone a PPARγ agonist, decreased IR in major metabolic tissues [22], dyslipidemia [53], and the hepatic lipid accumulation in iNOS-/- mice as suggested by decreased liver/body weight ratio.